Compare ENVA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENVA | CELC |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | N/A | 2017 |
| Metric | ENVA | CELC |
|---|---|---|
| Price | $157.42 | $111.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $159.50 | $100.13 |
| AVG Volume (30 Days) | 230.4K | ★ 629.3K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.62 | N/A |
| EPS | ★ 10.82 | N/A |
| Revenue | ★ $1,414,115,000.00 | N/A |
| Revenue This Year | $159.48 | N/A |
| Revenue Next Year | $16.33 | N/A |
| P/E Ratio | $14.56 | ★ N/A |
| Revenue Growth | ★ 20.78 | N/A |
| 52 Week Low | $79.41 | $7.58 |
| 52 Week High | $168.68 | $116.44 |
| Indicator | ENVA | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 53.84 | 60.08 |
| Support Level | $151.28 | $103.00 |
| Resistance Level | $164.00 | $112.69 |
| Average True Range (ATR) | 4.63 | 6.44 |
| MACD | -1.31 | 0.07 |
| Stochastic Oscillator | 47.69 | 70.07 |
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and and Brazil. Consumers apply for credit online, the company's technology platforms process the applications, and transactions are completed quickly and efficiently. Its customers are predominantly retail consumers and small businesses. Enova markets its financing products under the names CashNetUSA, NetCredit, OnDeck, Headway Capital, and Simplic. The company also operates a money transfer platform under the name Pangea. Geographically, the company generates a majority of its revenue from its business in the United States and the rest from other international countries.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.